Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model
- First Online:
- Cite this article as:
- Chang, Y., Hsu, C., Chang, C. et al. Invest New Drugs (2013) 31: 801. doi:10.1007/s10637-012-9906-7
Nanoliposomes are good drug delivery systems that allow the encapsulation of drugs into vesicles for their delivery. The objective of this study is to investigate the therapeutic efficacy of a new radio-therapeutics of 188Re-labeled pegylated liposome in a C26 murine colon carcinoma solid tumor model. The safety of 188Re-liposome was evaluated before radiotherapy treatment. The anti-tumor effect of 188Re-liposome was assessed by tumor growth inhibition, survival ratio and ultrasound imaging. Apoptotic marker in tumor was also evaluated by the TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling) method after injection of 188Re-liposome. The group treated with 188Re-liposome displayed slight loss in body weight and decrease in white blood cell (WBC) count 7 to 14 days post-injection. With respect to therapeutic efficacy, the tumor-bearing mice treated with 188Re-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI = 0.140; 80 day) than those treated with anti-cancer drug 5-FU (MGI = 0.195; 69 day) and untreated control mice (MGI = 0.413; 48 day). The ultrasound imaging showed a decrease in both tumor volume and number of blood vessels. There were significantly more apoptotic nuclei (TUNEL-positive) in 188Re-liposome-treated mice at 8 h after treatment than in control mice. These results evidenced the potential benefits achieved by oncological application of the radio-therapeutics 188Re-liposome for adjuvant cancer treatment.